CVRx Announces Strong First Quarter 2025 Financial Performance

CVRx Reports Preliminary First Quarter 2025 Financial Results

CAMBRIDGE, Mass., April 7, 2025 /PRNewswire/ -- CVRx, Inc. (Nasdaq: CVRX), a medical technology company focused on developing innovative, minimally invasive treatments for cardiovascular disease, today reported preliminary financial results for the first quarter ended March 31, 2025.

According to the preliminary results, CVRx's net revenue for the first quarter was approximately $2.5 million, compared to $1.8 million in the same period last year, representing a 38% increase. The company's net loss for the quarter was approximately $5.5 million, compared to a net loss of $7.1 million in the same period last year, representing a 22% reduction.

"We are pleased with our preliminary financial results for the first quarter, which demonstrate continued growth in our revenue and a reduction in our net loss," said Fernando Fernandez, President and CEO of CVRx. "Our focus on executing our business strategy and advancing our pipeline of innovative treatments for cardiovascular disease is yielding positive results. We are confident that our efforts will drive long-term growth and value creation for our shareholders."

CVRx's preliminary financial results for the first quarter are subject to the completion of its financial statements and the filing of its Quarterly Report on Form 10-Q with the Securities and Exchange Commission (SEC). The company expects to file its Quarterly Report on Form 10-Q with the SEC by May 15, 2025.

About CVRx, Inc.

CVRx, Inc. is a medical technology company focused on developing innovative, minimally invasive treatments for cardiovascular disease. The company's product, Barostim Neo, is a minimally invasive, implantable device designed to treat hypertension and heart failure. For more information, please visit the company's website at www.cvrx.com.